Pharmacogenetics and breast cancer management: current status and perspectives
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacogenetics and breast cancer management: current status and perspectives
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume 11, Issue 5, Pages 719-729
Publisher
Informa Healthcare
Online
2015-02-18
DOI
10.1517/17425255.2015.1008447
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer
- (2014) X. Han et al. ANNALS OF ONCOLOGY
- Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil
- (2014) David Jamieson et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy
- (2014) Göran Carlsson et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A systematic review of bevacizumab efficacy in breast cancer
- (2014) Iben Kümler et al. CANCER TREATMENT REVIEWS
- Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy
- (2014) Sonam Tulsyan et al. CLINICA CHIMICA ACTA
- The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer
- (2014) A. Backen et al. CLINICAL CANCER RESEARCH
- Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?
- (2014) Gerard Milano et al. CURRENT DRUG TARGETS
- CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
- (2013) K. Beelen et al. BREAST CANCER RESEARCH AND TREATMENT
- Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial
- (2013) Lise Roca et al. BREAST CANCER RESEARCH AND TREATMENT
- Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
- (2013) D W Miles et al. BRITISH JOURNAL OF CANCER
- Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case–control study of contralateral breast cancer risk in the WECARE Study
- (2013) Jennifer D. Brooks et al. CANCER CAUSES & CONTROL
- Influence of ABCB1 genetic variants in breast cancer treatment outcomes
- (2013) P. Chaturvedi et al. Cancer Epidemiology
- Erlotinib, Gefitinib, and Vandetanib Inhibit Human Nucleoside Transporters and Protect Cancer Cells from Gemcitabine Cytotoxicity
- (2013) V. L. Damaraju et al. CLINICAL CANCER RESEARCH
- CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
- (2013) M A Province et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical Implementation of Germ Line Cancer Pharmacogenetic Variants During the Next-Generation Sequencing Era
- (2013) N K Gillis et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacogenetic Influence of GST Polymorphisms on Anthracycline-Based Chemotherapy Responses and Toxicity in Breast Cancer Patients: A Multi-Analytical Approach
- (2013) Sonam Tulsyan et al. Molecular Diagnosis & Therapy
- Personalized medicine in oncology: where have we come from and where are we going?
- (2013) Fabrice André et al. PHARMACOGENOMICS
- Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen
- (2013) Cindy Serdjebi et al. PHARMACOGENOMICS
- Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency
- (2013) M C van Staveren et al. PHARMACOGENOMICS JOURNAL
- Pharmacogenomics of breast cancer therapy: An update
- (2013) Kelly Westbrook et al. PHARMACOLOGY & THERAPEUTICS
- Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab
- (2013) Fotios Loupakis et al. PLoS One
- Prognostic Significance of ESR1 Amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 Polymorphisms in Breast Cancer Patients
- (2013) Aleksandra Markiewicz et al. PLoS One
- CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel
- (2012) Daniel L. Hertz et al. BREAST CANCER RESEARCH AND TREATMENT
- GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer
- (2012) Tomohiro Miyake et al. CANCER SCIENCE
- CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
- (2012) M. P. Goetz et al. CLINICAL CANCER RESEARCH
- Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies
- (2012) Bo Gao et al. JOURNAL OF CLINICAL ONCOLOGY
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Meredith M. Regan et al. JNCI-Journal of the National Cancer Institute
- Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity
- (2012) Rafid Salim Jabir et al. PHARMACOGENOMICS
- Pharmacogenomics of Human ABC Transporter ABCC11 (MRP8): Potential Risk of Breast Cancer and Chemotherapy Failure
- (2011) Yu Toyoda et al. Anti-Cancer Agents in Medicinal Chemistry
- Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
- (2011) F Loupakis et al. BRITISH JOURNAL OF CANCER
- A Polymorphism in the Cytidine Deaminase Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome
- (2011) D. Caronia et al. CLINICAL CANCER RESEARCH
- Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients
- (2011) N. Azzopardi et al. CLINICAL CANCER RESEARCH
- Functional Significance of Genetic Polymorphisms in P-glycoprotein (MDR1, ABCB1) and Breast Cancer Resistance Protein (BCRP, ABCG2)
- (2011) Ichiro Ieiri Drug Metabolism and Pharmacokinetics
- Sudden Death Related to Toxicity in a Patient on Capecitabine and Irinotecan Plus Bevacizumab Intake: Pharmacogenetic Implications
- (2011) Laetitia Dahan et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrating pharmacogenetics into gemcitabine dosing—time for a change?
- (2011) Joseph Ciccolini et al. Nature Reviews Clinical Oncology
- Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle
- (2011) Guido Bocci et al. PHARMACOGENOMICS
- Association of CYP1B1 with hypersensitivity induced by Taxane therapy in breast cancer patients
- (2010) Roberta Rizzo et al. BREAST CANCER RESEARCH AND TREATMENT
- Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients
- (2010) Marie-Christine Etienne-Grimaldi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- ABCC11/MRP8 confers pemetrexed resistance in lung cancer
- (2010) Takehiro Uemura et al. CANCER SCIENCE
- Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer
- (2010) S. Yao et al. CLINICAL CANCER RESEARCH
- CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification
- (2010) W. Schroth et al. CLINICAL CANCER RESEARCH
- Routine Dihydropyrimidine Dehydrogenase Testing for Anticipating 5-Fluorouracil–Related Severe Toxicities: Hype or Hope?
- (2010) Joseph Ciccolini et al. Clinical Colorectal Cancer
- Impact of Cytidine Deaminase Polymorphisms on Toxicity After Gemcitabine: The Question Is Still Ongoing
- (2010) Elisa Giovannetti et al. JOURNAL OF CLINICAL ONCOLOGY
- CYP2C19*2polymorphism is associated with increased survival in breast cancer patients using tamoxifen
- (2010) Rikje Ruiter et al. PHARMACOGENOMICS
- Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma
- (2009) R. Marechal et al. CLINICAL CANCER RESEARCH
- Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
- (2009) Werner Schroth JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Irinogenetics: How Many Stars Are There in the Sky?
- (2009) Ron H.J. Mathijssen et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based Chemotherapies
- (2009) Joseph Ciccolini et al. JOURNAL OF CLINICAL ONCOLOGY
- Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients
- (2009) Siew-Kee Low et al. JOURNAL OF HUMAN GENETICS
- The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors
- (2009) L. Jain et al. MOLECULAR CANCER THERAPEUTICS
- Influence of theVEGF-A936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancer
- (2009) Jean-Louis Formento et al. PHARMACOGENOMICS
- Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile
- (2008) Cedric Mercier et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia
- (2008) Kazuma Kiyotani et al. CANCER SCIENCE
- Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients
- (2008) C. Tibaldi et al. CLINICAL CANCER RESEARCH
- Pharmacogenetic Pathway Analysis of Docetaxel Elimination
- (2008) SD Baker et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression
- (2008) N. Ribelles et al. CURRENT DRUG METABOLISM
- Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide
- (2008) Corine Ekhart et al. Pharmacogenetics and Genomics
- Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors
- (2008) Romano Danesi et al. PHARMACOGENOMICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started